reason report
patienc need unlock perrigo pt
bottom line stock finish today guidanc midpoint
indic y/i growth top line flat bottom line
simpli put shape invest year believ
time requir manag execut long-term
plan drive earn growth revenu note manag
conservat high ridg gx proair particular also
take temper view look addit quarter strong csca
perform margin expect flat manag
make invest busi overal continu stay
sidelin look better visibl whether new
busi strategi drive sale earn growth
lower pt reiter mp rate
csca saw multipl tailwind unclear long growth
driver persist strength driven factor faster
growth key product categori particular cough/cold allergi
smoke cessat increas store brand penetr
share within store brand improv scale
e-commerc busi new product launch nutrit
busi appear new product growth upper
respiratori digest health nutrit particular see
potenti share growth continu across board
quit assum result usher
improv across board look continu strong
perform upsid current estim y/i organ growth
also note full year impact ranir well contribut
high ridg asset collect drive overal csca y/i estim
growth close high ridg acquisit appear
earlier incorpor manag guidanc
see upsid potenti well margin note manag
invest busi addit high ridg asset
put downward pressur margin believ oper
margin improv
csci look work-in-progress year look
revenu margin improv manag note
impact franc improv quit yet
revenu advers affect currenc manag
indic ex-ranir cc growth year grow
market share particular uk store brand busi continu
roll-out new product launch believ revenu get
rang longer term margin improv like take longer
given margin uk biz ranir need see near-term
improv becom confid high-teen oper
margin profil segment longer term
compani inform svb leerink llc research
revenu
ev/ebitda multipl incl
net debt total capit
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
gx proair wildcard take conserv
view opportun believ manag well
manag indic conservat gx proair due uncertainti
net price also see slow ramp market share given time
capac build model product
longer term see rx margin continu declin gx proair
partner product limit visibl addit key
chang model increas revenu
larg due contribut high ridg asset
includ well earlier entri gx proair vs
prior estim impli y/i growth low
end manag guidanc rang howev see gross
margin declin anoth bp lower margin ranir high
ridg along gx proair add product mix overal
lower ep low end
manag guidanc rang ebitda
lower vs appli multipl
result revis pt vs previous
rate market perform believ consum self-car america csca like
continu grow low-singl digit consum self-car csci also grow
low-singl digit growth potenti manag initi take time play
view howev unclear decis separ rx busi
immedi unlock valu enhanc growth consum healthcar segment
current still limit visibl medium-/long-term growth trajectori
busi final see signific uncertainti around tysabri royalti tax liabil rule
ireland us whether may abl win appeal long take
get appeal decis
use ebitda appli weight averag ev/ebitda multipl
includ potenti tax-rel liabil arriv pt
limit rx-to-otc switch opportun and/or delay new rx over-the-counter product launch
could result share trade lower expect initi drive busi may
success anticip lead share perform better expect uncertainti
time and/or natur separ gener busi uncertainti time
eventu liabil amount relat tysabri ip sale
figur chang model
svb leerink estim note number except ep margin
note revenu
varianc analysissvb leerinkami fadiaconfer call analystdi changevalu changevarianceconsensusactu vs conssegmentscsc dilut non-gaap adjustmentstot one-tim net perrigo compani plc
note revenu
brand
svb leerink llc equiti research compani file
type event
event trial detail
date known
up/down
expect
clariti irish ir tax liabil
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
number except per share data
number except per share data
number except per share data
pain sleep-aid
total pain sleep-aid
number except per share data
skincar person hygien
total skincar person hygien
number except per share data
skincar person hygien
pain sleep-aid
number except per share data
gx finacea foam azela acid progress month stay expir juli
gx soolantra cream ivermectin rosacea ftf case progress
number except per share data
tysabri royalti stream fair valu
payrol relat tax
number except per share data
adjust reconcil ni net cash oper
tysabri toyalti stream chang fair valu
loss extinguish debt
impair equiti invest net
decreas increas work capit
proce royalti right
acquisit businesses/asset net cash acquir
proceed sale busi
settlement acquisition-rel foreign currenc deriv
purchas properti plant equip capital-expenditure
net invest
borrow repay revolv credit/oth net
premium earli debt retir
issuanc ordinari share
net financ
effect exchang rate chang cash/ cash equival
net chang equival
